Literature DB >> 11573863

Prophylaxis for paclitaxel hypersensitivity reactions.

P E Kintzel1.   

Abstract

OBJECTIVE: To evaluate clinical literature supporting the prophylactic use of single-dose intravenous dexamethasone to prevent hypersensitivity reactions (HSRs) to paclitaxel infusion. DATA SOURCES: Clinical literature accessed through MEDLINE (from 1986 to 2000). DATA SYNTHESIS: Prophylaxis for paclitaxel-related HSRs generally includes repeated dexamethasone doses beginning 12 hours before paclitaxel, and administration of diphenhydramine plus a histamine2-receptor antagonist 30 minutes before infusion of paclitaxel. Singe-dose intravenous dexamethasone administered with ancillary medications 30 minutes before infusion of paclitaxel has been used to prevent regimen-related HSRs.
CONCLUSIONS: Single-dose intravenous dexamethasone can be used in combination with appropriate ancillary medications to prevent paclitaxel-related HSRs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11573863     DOI: 10.1345/aph.10287

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  9 in total

1.  Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum.

Authors:  Jae-Lyun Lee; Jin-Hee Ahn; Se Hoon Park; Ho Young Lim; Jung Hye Kwon; Shin Ahn; Cheryn Song; Jun Hyuk Hong; Choung-Soo Kim; Hanjong Ahn
Journal:  Invest New Drugs       Date:  2011-10-20       Impact factor: 3.850

Review 2.  Engineering Biomaterial-Drug Conjugates for Local and Sustained Chemotherapeutic Delivery.

Authors:  Jeannine M Coburn; David L Kaplan
Journal:  Bioconjug Chem       Date:  2015-03-02       Impact factor: 4.774

3.  Design, synthesis and bioevaluation of an EphA2 receptor-based targeted delivery system.

Authors:  Elisa Barile; Si Wang; Swadesh K Das; Roberta Noberini; Russell Dahl; John L Stebbins; Elena B Pasquale; Paul B Fisher; Maurizio Pellecchia
Journal:  ChemMedChem       Date:  2014-03-26       Impact factor: 3.466

4.  Pre-medication protocols for the prevention of paclitaxel-induced infusion related reactions: a systematic review and meta-analysis.

Authors:  Samuel Dubinsky; Deep Patel; Xiang Wang; Amirrtha Srikanthan; Terry L Ng; Corey Tsang
Journal:  Support Care Cancer       Date:  2022-02-12       Impact factor: 3.603

5.  Paclitaxel in a novel formulation containing less Cremophor EL as first-line therapy for advanced breast cancer: a phase II trial.

Authors:  Ta-Chung Chao; Zyting Chu; Ling-Ming Tseng; Tzeon-Jye Chiou; Ruey-Kuen Hsieh; Wei-Shu Wang; Chueh-Chuan Yen; Muh-Hwa Yang; Liang-Tsai Hsiao; Jin-Hwang Liu; Po-Min Chen
Journal:  Invest New Drugs       Date:  2005-03       Impact factor: 3.850

Review 6.  Hypersensitivity reactions to chemotherapeutic drugs.

Authors:  Gillian M Shepherd
Journal:  Clin Rev Allergy Immunol       Date:  2003-06       Impact factor: 8.667

7.  Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens.

Authors:  J S Kloover; M A den Bakker; H Gelderblom; J P van Meerbeeck
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

8.  An Open-Label, Randomized, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel as First-Line Treatment for Ovarian Cancer: A Korean Gynecologic Oncology Group Study (KGOG-3021).

Authors:  Shin-Wha Lee; Yong-Man Kim; Chi Heum Cho; Young Tae Kim; Seok Mo Kim; Soo Young Hur; Jae-Hoon Kim; Byoung-Gie Kim; Seung-Cheol Kim; Hee-Sug Ryu; Soon Beom Kang
Journal:  Cancer Res Treat       Date:  2017-03-21       Impact factor: 4.679

9.  Meta-analysis of the effects of oral and intravenous dexamethasone premedication in the prevention of paclitaxel-induced allergic reactions.

Authors:  Fu-Chao Chen; Lin-Hai Wang; Xiao-Yu Zheng; Xiu-Min Zhang; Jun Zhang; Lin-Jun Li
Journal:  Oncotarget       Date:  2017-03-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.